ARTICLE | Clinical News
Jinarc tolvaptan regulatory update
March 16, 2015 7:00 AM UTC
EMA’s CHMP recommended approval of Jinarc tolvaptan from Otsuka to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults wi...